PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting
PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The poster will highlight immunological data from patients enrolled in the three first cohorts of the on-going Phase I/II trial evaluating PDC*lung01, an 'off-the-shelf' cancer vaccine for the treatment of patients with non-small cell lung cancer (NSCLC).
Title: Induction of circulating antitumor specific CD8+ T cells in patients with non-small cell lung cancer treated with an allogeneic plasmacytoid dendritic-cell based cancer vaccine with or without anti- PD-1 treatment
. Abstract Number: #156
· Presentation Topic: Therapeutic Vaccination
· Session Time: Poster Session II, May 4th 3:30 - 6pm CET
· Location: North Foyer
· Speaker: Sebastien Michel (PDC*line Pharma)
Abstract of the poster available through this link: https://lnkd.in/edpF5i8d Page 131
CIMT is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. Since the Association was founded, hundreds of scientific papers have documented the discoveries and advancements in cancer immunology.
More information about this meeting is available here: https://lnkd.in/dHyfjun